ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)
HKD 5.36
(-1.83%)
HKD 5.36
(-1.83%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 386 Thousand | 538 Thousand | 5.06 Million |
| Cost of Revenue | -38.65 Thousand | - | - |
| Gross Profit | 424.65 Thousand | 538 Thousand | 5.06 Million |
| Operating Expenses | 365.05 Million | 382.71 Million | 220.41 Million |
| Selling, General and Administrative Expenses | 80.42 Million | 92.79 Million | 48.31 Million |
| Research and Development Expenses | 291.94 Million | 277.34 Million | 175.95 Million |
| Other Expenses | 58 Thousand | -55.54 Million | -511.53 Million |
| Cost and Expenses | 365.05 Million | 382.71 Million | 220.41 Million |
| Operating Income | -364.67 Million | -402.1 Million | -734.37 Million |
| Interest Expense | 1.52 Million | 787 Thousand | 891 Thousand |
| Income Tax Expense | - | 17.38 Million | 12.93 Million |
| Earnings before Tax | -379.45 Million | -402.89 Million | -732.94 Million |
| Net Income | -379.45 Million | -402.89 Million | -732.94 Million |
| Earnings Per Share Basic | -1.05 | -1.08 | -1.96 |
| Earnings Per Share Diluted | -1.05 | -1.08 | -1.96 |
| Weighted Average Shares Outstanding | 361.81 Million | 373.23 Million | 373.23 Million |
| Weighted Average Shares Outstanding (Diluted) | 361.81 Million | 373.23 Million | 373.23 Million |
| Gross Margin | 1.10 | 1.00 | 1.00 |
| EBIT Margin | -920.60 | -714.67 | -142.33 |
| Profit Margin | -983.05 | -748.87 | -144.65 |
| EBITDA | -355.35 Million | -384.49 Million | -718.88 Million |
| Earnings Before Tax Margin | -944.75 | -747.41 | -144.93 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 386.29 Thousand | 389.62 Thousand | 324.1 Thousand | 386 Thousand | 4.15 Million | 97.26 Thousand |
| Cost of Revenue | - | - | -3.93 Million | -38.65 Thousand | - | 50.82 Thousand |
| Gross Profit | 386.29 Thousand | 389.62 Thousand | 4.26 Million | 424.65 Thousand | 4.15 Million | 46.43 Thousand |
| Operating Expenses | 80.16 Million | 80.85 Million | 207.13 Million | 365.05 Million | 118.51 Million | 178.74 Million |
| Selling, General and Administrative Expenses | 16.15 Million | 16.29 Million | 30.11 Million | - | 21 Million | 33.88 Million |
| Research and Development Expenses | 64 Million | 64.56 Million | 177.02 Million | - | 87.87 Million | 144.85 Million |
| Other Expenses | - | - | - | 58 Thousand | - | - |
| Cost and Expenses | 80.16 Million | 80.85 Million | 219.33 Million | 365.05 Million | 118.51 Million | 191.51 Million |
| Operating Income | -79.77 Million | -80.46 Million | -219.01 Million | -401.18 Million | -105.28 Million | -191.42 Million |
| Interest Expense | 1.54 Million | - | 965.82 Thousand | 1.52 Million | - | 712.5 Thousand |
| Income Tax Expense | 4.00 | -1.00 | 5.00 | 9.47 Million | - | -4.00 |
| Earnings before Tax | -89.05 Million | -89.82 Million | -225.38 Million | -379.45 Million | -111.88 Million | -193.2 Million |
| Net Income | -89.05 Million | -89.82 Million | -225.38 Million | -379.45 Million | -111.88 Million | -193.2 Million |
| Earnings Per Share Basic | -0.24 | -0.24 | -0.60 | - | -0.30 | -0.52 |
| Earnings Per Share Diluted | -0.24 | -0.24 | -0.60 | - | -0.30 | -0.52 |
| Weighted Average Shares Outstanding | 374.15 Million | 374.15 Million | 374.15 Million | 361.81 Million | 367.52 Million | 374.15 Million |
| Weighted Average Shares Outstanding (Diluted) | 374.15 Million | 374.15 Million | 374.15 Million | 361.81 Million | 367.52 Million | 374.15 Million |
| Gross Margin | 1.00 | 1.00 | 13.15 | 1.10 | 1.00 | 0.48 |
| EBIT Margin | -198.48 | -198.48 | -638.11 | - | -24.54 | -1836.82 |
| Profit Margin | -230.54 | -230.54 | -695.43 | -983.05 | -26.93 | -1986.41 |
| EBITDA | -76.67 Million | -77.33 Million | -206.81 Million | - | -101.95 Million | -178.65 Million |
| Earnings Before Tax Margin | -206.51 | -206.51 | -675.76 | -1039.35 | -25.34 | -1968.11 |
3357
1907
002811
TSKB
082920
EIM